Skip to main content
. Author manuscript; available in PMC: 2017 Apr 11.
Published in final edited form as: NPJ Parkinsons Dis. 2015 Jun 11;1:15011. doi: 10.1038/npjparkd.2015.11

Table 2.

Antiparkinsonian and other medication use

Median (range) or number (%)
 Significance P-value
Fallers (n = 27) Non-fallers (n = 60)
Dopaminergic medication
    LEU (mg)     734.3 (1616.7)     330.8 (1700)       0.009
    Levodopa    22/27 (81%)    36/60 (60%)       0.05
    Dopamine agonist    17/27 (46%)    32/60 (53%)       0.40
    MAOB inhibitor      3/27 (11%)      8/60 (13%)       0.77
    COMT inhibitor    10/27 (37%)    14/60 (23%)       0.19
    Amantadine      7/27 (26%)      4/60 (7%)       0.01
Other medication
    Antidepressants    10/27 (37%)      4/60 (7%)    < 0.001
    Neuroleptics    11/27 (41%)      5/60 (8%)    < 0.001
    Sleep medication      2/27 (7%)      3/60 (5%)       0.66

Abbreviation: LEU, Levodopa-equivalent unit.